Page 101 - SSIB 2012 PROGRAM

LOTTE B. KNUDSEN

Senior scientist

Apply by

August 1

st

2012

www.novonordisk-us.com/innovation

Diabetes

Innovation

Award Program

NOVEL PROTEIN THERAPEUTICS AND

TECHNOLOGIES FOR DIABETES AND OBESITY

Novo Nordisk R&D has launched a

research award program to support

both new and established scientists

1

exploring novel hypotheses in protein-

based therapeutics and technologies

for diabetes and obesity. The aim of this

new research award program is to help

scientists substantiate early innovation

research efforts and clarify if their

hypotheses have the potential to result

in the cure, prevention and/or improved

treatment of diabetes and obesity.

Under the new program, Novo Nordisk

R&D offers two types of research

funding opportunities: “Early Research

Exploration” or “Proof of Principle”.

These awards are intended for nonclinical

research only. Research projects can be

supported for up to two years.

Early Research Exploration Award

$250,000

2

up to two years

Research support for early-stage hypotheses that do not yet have

preliminary data but show considerable promise for advancing the

treatment of diabetes or obesity

Proof of Principle (PoP) Award

$500,000

2

up to two years

Research support for the validation of early stage innovations with

enough supporting data to conclude on nonclinical PoP studies.

Applicants have the option to apply for additional scientific support from

Novo Nordisk that would provide access to our R&D scientists and facilities

to conduct PoP studies.

1

Research support is open to scientists and academic research institutions in the US and Canada only

2

Direct costs that can be specifically identified as part of the research project. In addition, the Award Program covers the facility and administrative

(indirect) costs needed to conduct research. Indirect costs will be covered according to the host institution rate based on current government rules